Insider Buying: Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Buys 7,851 Shares of Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt purchased 7,851 shares of Shuttle Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The stock was bought at an average cost of $3.54 per share, for a total transaction of $27,792.54. Following the purchase, the insider directly owned 90,407 shares in the company, valued at $320,040.78. This trade represents a 9.51% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.51, for a total transaction of $31,667.22.
• On Wednesday, July 1st, Financial Lp Hrt bought 3,959 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average price of $3.30 per share, for a total transaction of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt bought 6,755 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average cost of $3.23 per share, for a total transaction of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt purchased 25,836 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average cost of $3.44 per share, with a total value of $88,875.84.

Shuttle Pharmaceuticals Stock Performance

NASDAQ SHPH traded down $0.24 on Tuesday, reaching $3.26. 109,982 shares of the stock traded hands, compared to its average volume of 543,961. Shuttle Pharmaceuticals Holdings, Inc. has a 12 month low of $2.90 and a 12 month high of $55.90. The company has a market cap of $2.08 million, a price-to-earnings ratio of -0.07 and a beta of 0.29. The company has a fifty day moving average price of $5.57 and a 200-day moving average price of $10.46.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC acquired a new position in shares of Shuttle Pharmaceuticals during the fourth quarter valued at about $26,000. Boothbay Fund Management LLC acquired a new stake in Shuttle Pharmaceuticals in the 4th quarter worth approximately $37,000. Ikarian Capital LLC purchased a new stake in Shuttle Pharmaceuticals during the 4th quarter worth approximately $124,000. Finally, Connective Capital Management LLC acquired a new position in Shuttle Pharmaceuticals during the 3rd quarter valued at approximately $357,000. 4.58% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Weiss Ratings upgraded shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a research report on Saturday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .